Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  TherapeuticsMD Inc    TXMD

THERAPEUTICSMD INC (TXMD)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/11/2018 06/12/2018 06/13/2018 06/14/2018 06/15/2018 Date
7.04(c) 6.99(c) 6.78(c) 6.88(c) 7.13(c) Last
3 651 225 3 424 836 3 215 966 2 279 470 7 296 078 Volume
-5.12% -0.71% -3.00% +1.47% +3.63% Change
More quotes
Financials (USD)
Sales 2018 21,7 M
EBIT 2018 -113 M
Net income 2018 -114 M
Finance 2018 16,8 M
Yield 2018 -
Sales 2019 133 M
EBIT 2019 -38,3 M
Net income 2019 -52,5 M
Finance 2019 50,5 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 70,3x
EV / Sales2019 11,2x
Capitalization 1 544 M
More Financials
Company
TherapeuticsMD, Inc. operates as a healthcare company, which focuses on developing and commercializing products for women.Its technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and... 
Sector
Pharmaceuticals
Calendar
06/25 | 02:00pmShareholder meeting
More about the company
Surperformance© ratings of TherapeuticsMD Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on THERAPEUTICSMD INC
06/09THERAPEUTICSMD : Announces Draw Down of $75 Million Under Term Loan with MidCap ..
AQ
06/07THERAPEUTICSMD, INC. : Creation of a Direct Financial Obligation or an Obligatio..
AQ
06/07THERAPEUTICSMD : Announces Draw Down of $75 Million Under Term Loan with MidCap ..
BU
06/07THERAPEUTICSMD : to Present at Goldman Sachs 39th Annual Global Healthcare Confe..
BU
06/06THERAPEUTICSMD : Announces Multiple Presentations at the International Menopause..
BU
06/04THERAPEUTICSMD : to Present at Jefferies 2018 Healthcare Conference
BU
06/04THERAPEUTICSMD, INC. : Regulation FD Disclosure, Financial Statements and Exhibi..
AQ
05/31THERAPEUTICSMD : Announces Clinical Abstract at the 2018 ASCO Annual Meeting
BU
05/31THERAPEUTICSMD : FDA approval for TherapeuticsMD, one year after initial rejecti..
AQ
05/31THERAPEUTICSMD : FDA approves Boca Raton company's treatment for painful sex
AQ
More news
Sector news : Specialty & Advanced Pharmaceuticals
06/16International fund managers turn to financials, tech as trade worries rise
RE
06/15BAYER : Japan suspends sale of Canadian wheat after GMO wheat found in Alberta
RE
06/15UK's Indivior will fight U.S. FDA's approval for copycat drug
RE
06/15Indivior Shares Drop After U.S. Approves Suboxone Generics
DJ
06/15UK's Indivior to seek injunction after rival gets FDA approval for generics
RE
More sector news : Specialty & Advanced Pharmaceuticals
Latest Tweets
06:56p$TXMD  
06:26pTherapeuticsMD $TXMD Shares Gap Up to $6.88  
10:49aBidaskClub Lowers TherapeuticsMD $TXMD to Sell  
06/16TherapeuticsMD $TXMD Now Covered by Analysts at JPMorgan Chase & Co.  
06/15+Initiations 6/15: $AVGO $BRG $CFRX $CIM $CPST $DK $EDRY $ERF $EVRG $FDC $GLU.. 
More tweets
Qtime:24
News from SeekingAlpha
12:56pTHERAPEUTICSMD : More Room To Grow? 
06/15PREMARKET GAINERS AS OF 9 : 05 am (06/15/2018) 
06/15Premarket analyst action - healthcare 
06/04TherapeuticsMD (TXMD) Investor Presentation - Slideshow 
06/04Game Plan For The Week - Cramer's Mad Money (6/1/18) 
Chart THERAPEUTICSMD INC
Duration : Period :
TherapeuticsMD Inc Technical Analysis Chart | TXMD | US88338N1072 | 4-Traders
Technical analysis trends THERAPEUTICSMD INC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 15,5 $
Spread / Average Target 117%
EPS Revisions
Managers
NameTitle
Robert G. Finizio Chief Executive Officer & Director
John C. K. Milligan President & Director
Tommy George Thompson Chairman
Jason S. Spitz VP-Operations, Marketing & Commercial Development
Daniel Alan Cartwright Chief Financial Officer, Treasurer & VP
Sector and Competitors
1st jan.Capitalization (M$)
THERAPEUTICSMD INC18.05%1 544
ABBVIE3.85%158 006
MERCK KGAA-6.25%12 663
KYOWA HAKKO KIRIN CO LTD6.08%12 281
JAZZ PHARMACEUTICALS PLC32.27%10 685
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD67.36%9 912